Abstract
Background Peanut allergies are common and can be life-threating for sensitised individuals. Peanut allergens share significant amino acid homology with those of other legumes and tree nuts, but their cross-reactivity still remains unclear. Objective We sought to determine the clinical significance of the cross-reactivity of peanut allergens with those of walnut and soybean. Methods Pooled sera from eight subjects with both peanut and walnut specific IgE were investigated in an inhibition test. After the sera were incubated with either peanut or walnut protein extracts, the quantity of IgE antibodies against the peanut and walnut was measured using an immunoCAP test. Likewise, pooled sera from 18 subjects with both peanut and soybean specific IgE antibodies were incubated with either peanut or soybean protein extracts and evaluated with a peanut and soybean immunoCAP test. SDS-PAGE and immunoblotting were also performed with peanut, walnut and soybean protein extracts and relevant sera. Results Peanut specific IgE was inhibited up to 20% and 26% by walnut and soybean protein extracts, respectively. In reverse, walnut and soybean specific IgE were inhibited up to 21% and 23% by peanut protein extracts, respectively. In the immunoblot analysis, pooled serum from the subjects with peanut specific IgE antibodies reacted with walnut protein extracts significantly. Conclusion Although the clinical significance of the cross-reactivity of peanut specific IgE with walnut and soybean protein extracts has not been established, we believe that individuals who are allergic to peanuts need to be cautious about consuming walnuts and soybeans.
Original language | English |
---|---|
Pages (from-to) | 524-530 |
Number of pages | 7 |
Journal | Allergologia et Immunopathologia |
Volume | 44 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2016 Nov 1 |
Bibliographical note
Funding Information:This study was supported by a grant from the Korea Healthcare Technology R&D Project ( A092076 ) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare , Republic of Korea (grant number: HI11C1404 and HI14C0234 ). The authors thank Phadia Korea (Seoul, Korea) for the gift of the immunoCAP liquid reagents.
Publisher Copyright:
© 2016 SEICAP
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
- Pulmonary and Respiratory Medicine